These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 11117106

  • 1. [Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].
    Hottelart C, Bako G, Oprisiu R, Georgita A, Presne C, Sarraj A, Morinière P, el Esper N, Fournier A.
    Nephrologie; 2000; 21(6):275-82. PubMed ID: 11117106
    [Abstract] [Full Text] [Related]

  • 2. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S, Oprisiu R, Benamar L, Said S, Tataru Albu A, Arsenescu I, el Esper N, Morinière P, Fournier A.
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [Abstract] [Full Text] [Related]

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 4. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
    Fournier A, Oprisiu R, Hottelart C, Yverneau PH, Ghazali A, Atik A, Hedri H, Said S, Sechet A, Rasolombololona M, Abighanem O, Sarraj A, El Esper N, Moriniere P, Boudailliez B, Westeel PF, Achard JM, Pruna A.
    Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
    [Abstract] [Full Text] [Related]

  • 5. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Jul; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 6. Renal ostodystrophy during the developing stage of maintenance dialysis in Transylvania. Early development of periarticular calcifications and beta 2 microglobulin amyloidosis in spite of a relatively good prevention of secondary hyperparathyroidism.
    Oprisiu R, Bolosiu H, Boca I, Theodoru C, Elefterescu R, Brazier M, el Esper I, Leflon P, Ledeme C, Fournier A, Heinze V.
    Ann Med Interne (Paris); 1998 Mar; 149(2):67-75. PubMed ID: 11490527
    [Abstract] [Full Text] [Related]

  • 7. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.
    Fournier A, Morinière PH, Oprisiu R, Yverneau-Hardy P, Westeel PF, Mazouz H, el Esper N, Ghazali A, Boudailliez B.
    Nephron; 1995 Mar; 71(3):254-83. PubMed ID: 8569975
    [Abstract] [Full Text] [Related]

  • 8. [Vitamin D treatment and renal osteodystrophy: indications and modalities].
    Fournier A, Morinière P, Yverneau-Hardy P, Westeel PF, Mazouz H, el Esper N, Ghazali A, Boudailliez B.
    Nephrologie; 1995 Mar; 16(2):165-90. PubMed ID: 7753302
    [Abstract] [Full Text] [Related]

  • 9. [Hyperparathyroidism secondary to renal insufficiency. Physiopathology, clinicoradiological aspects and treatment].
    Ben Hamida F, Ghazali A, Boudzernidj M, Amar M, Morinière P, Westeel P, Fournier A.
    Ann Endocrinol (Paris); 1994 Mar; 55(5):147-58. PubMed ID: 7857079
    [Abstract] [Full Text] [Related]

  • 10. Use of alkaline calcium salts as phosphate binder in uremic patients.
    Fournier A, Morinière P, Ben Hamida F, el Esjer N, Shenovda M, Ghazali A, Bouzernidj M, Achard JM, Westeel PF.
    Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
    [Abstract] [Full Text] [Related]

  • 11. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P, Maurouard C, Boudailliez B, Westeel PF, Achard JM, Boitte F, el Esper N, Compagnon M, Maurel G, Bouillon R.
    Nephron; 1992 Oct; 60(2):154-63. PubMed ID: 1552999
    [Abstract] [Full Text] [Related]

  • 12. Strategies to minimize bone disease in renal failure.
    Martin KJ, González EA.
    Am J Kidney Dis; 2001 Dec; 38(6):1430-6. PubMed ID: 11728986
    [Abstract] [Full Text] [Related]

  • 13. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?
    Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Morinière P, Garabedian M, Eastwood J, Fournier A.
    Kidney Int; 1999 Jun; 55(6):2169-77. PubMed ID: 10354266
    [Abstract] [Full Text] [Related]

  • 14. Prevention of metabolic bone disease in the pre-end-stage renal disease setting.
    Coburn JW, Elangovan L.
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772
    [Abstract] [Full Text] [Related]

  • 15. Renal osteodystrophy and aluminum bone disease in CAPD patients.
    Gokal R.
    Clin Nephrol; 1988 Dec; 30 Suppl 1():S64-7. PubMed ID: 3052962
    [Abstract] [Full Text] [Related]

  • 16. Management of renal osteodystrophy in children.
    Tasic V.
    Turk J Pediatr; 2005 Dec; 47 Suppl():13-8. PubMed ID: 15884662
    [Abstract] [Full Text] [Related]

  • 17. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L, Daugaard H, Nielsen PK, Jensen LT, Egsmose C, Olgaard K.
    Nephron; 1996 Dec; 74(1):89-103. PubMed ID: 8883025
    [Abstract] [Full Text] [Related]

  • 18. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ, Shaheen FA.
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [Abstract] [Full Text] [Related]

  • 19. [Ultrasonography methods in the diagnosis of renal osteodystrophy].
    Tomić-Brzac H, Pavlović D.
    Acta Med Croatica; 2004 Jan; 58(1):43-9. PubMed ID: 15125393
    [Abstract] [Full Text] [Related]

  • 20. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
    Morinière P, Fournier A, Leflon A, Hervé M, Sebert JL, Grégoire I, Bataille P, Guéris J.
    Nephron; 1985 Jan; 39(4):309-15. PubMed ID: 3982576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.